Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move

Reuters

2025/07/28

Adaptimmune <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move

Adaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554776684"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554776684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554776684?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554776684","market":"nz","top_or_hot":-1,"title":"Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a> has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a> has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL44mkPC:1","article_id":"2554776684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554776684","pubTimestamp":1753702266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","SUPN":"Supernus Pharmaceuticals"},"translate_title":"Adaptimmune Therapeutics宣布战略举措向美国WorldMeds出售关键细胞疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAP":0.9,"SUPN":0.9},"content_text":"Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    \n\nAdaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}